Fidasimtamab, referred to as DLTV – 1504, represents the innovative approach in the battle against multiple myeloma. This therapy a dual-specific antibody designed to concurrently engage CD3-positive https://ibi315397421.pointblog.net/fidasimtamab-this-new-hope-in-relapsed-refractory-myeloma-treatment-95580771